MannKind Corporation

MannKind Corporation

MNKDยทNASDAQ

$3.36

-2.0%
HealthcareBiotechnology

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

At a Glance

Live Snapshot
Market Cap$1.04B
EPS0.0200
P/E Ratio168.00
Earnings Date08/05/2026

No Dividend Yield Data

MNKD has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

MNKD has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

MNKD has not reported any net dividends paid values in the available annual periods.

MannKind Corporation

MannKind Corporation Dividend History

MNKD ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

MNKD Dividend Payment History

MNKD ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
mnkd

MannKind Corporation Payout Ratio Analysis

MNKD ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
5.86M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Excellent FCF coverage. Dividend is well-supported by actual cash generation with ample room for increases and business reinvestment.

Sustainability
Fair

Dividend sustainability questionable. Monitor closely for signs of stress. Consider whether yield justifies the risk.